---

CLICK PLAY ABOVE to watch our announcement video.

Two leading foundations in the field of pediatric brain cancer research funding, Michael Mosier Defeat DIPG Foundation and The ChadTough Foundation, are uniting as one organization, ChadTough Defeat DIPG Foundation, to elevate and amplify their impact on finding a cure for DIPG.

In September 2014, two families, 500 miles away from each other, were hit with the most devastating news imaginable; each of their sons was diagnosed with the deadliest form of pediatric brain cancer and was given just 9 months to live.

While searching for hope and answers, Tammi and Jason Carr, in Michigan, and Jenny and Mark Mosier, in Maryland, began a journey through the darkest days of their lives.  By the end of the following year, each family endured the inevitable heartbreaking loss of their sons, Chad Carr, age 5, and Michael Mosier, age 6, to diffuse intrinsic pontine glioma (DIPG).

Throughout that excruciating time, the Carrs and Mosiers uncovered their shared passion for honoring their sons through raising research dollars. They, like so many other DIPG families, desperately wanted to help change the outlook for future families forced to face the horror of DIPG. Both families established foundations with a common goal — to find a cure for DIPG.

Jason and Tammi Carr established The ChadTough Foundation shortly after Chad was diagnosed. Through social media, Tammi discovered the power her voice carried in raising awareness. The community around her was inspired to help, and soon it wasn’t just her town of Saline rallying behind the mission. With a long family history with the University of Michigan, alumni from across the nation also began to surround the Carr family with support. Through Tammi and Jason’s committed efforts, their message eventually spread throughout Michigan, then across the United States and beyond. Over time, other families joined the Carrs’ efforts to fund promising research by becoming family partners.

Michael Mosier Defeat DIPG Foundation assembled a Scientific Advisory Council, composed of leading experts on DIPG. The purpose of the council was to conduct a rigorous review and scoring of grant applications submitted to the foundation, and to make recommendations to the Defeat DIPG Board of Directors to ensure the Michael Mosier Defeat DIPG Foundation effectively used its resources to fund the most innovative DIPG research projects.

The Mosiers, too, felt compelled to take action against DIPG. Given the lack of research funding for this disease, they felt it was imperative to speak out and raise funds for research so that new, effective treatments could become a reality.

“There was this huge void after we lost Michael,” explained Jenny Mosier. “Mark and I wanted to channel our heartache into something good and try to change the future for other families who would one day be in our shoes.” In 2015, the couple founded Michael Mosier Defeat DIPG Foundation. Other families across the country soon joined their efforts, as well, by becoming chapters or partner families.

When the Carrs learned of Defeat DIPG’s Scientific Advisory Council, they were eager to get involved.

“The Scientific Advisory Council the Mosiers put together is incredible,” said Jason Carr. “It’s made up of some of the best minds out there working to eradicate DIPG. As soon as Jenny and Mark told us what they were doing, we knew we had to be a part of it.”

“We admired the impact the Carrs were making on pediatric brain cancer research through The ChadTough Foundation,” said Mark Mosier. “Given our shared mission for finding a cure, we realized that combining our resources provided an opportunity for both organizations to amplify our research funding to fund more projects at a higher level.”

The two foundations decided to join forces to fund research together, and in the last 4 years, they have jointly committed $7 million across 21 institutions around the world. In addition to the research they have funded together, the two organizations have committed another $5 million individually, bringing the total to over $12 million in committed research funding.

Now, after four years of working together in the fight against pediatric brain cancer, The ChadTough Foundation and Michael Mosier Defeat DIPG Foundation have announced they will officially merge and become ChadTough Defeat DIPG Foundation. This union positions them to leverage the strengths of each, eliminate duplication, and gain efficiencies to maximize the amount of funds that can be granted toward the mission of inspiring and funding game-changing research in the field of pediatric brain cancer with an emphasis on the deadliest form, DIPG.

Foundations like ChadTough and Defeat DIPG are the primary source of funding for researchers working toward a cure for DIPG. Less than 4% of government cancer research funding is directed to all forms of pediatric cancer, with less than 1% directed to all forms of pediatric brain cancer. The funding provided so far from the two foundations, as well as others, has transformed the outlook for DIPG from hopeless to hopeful, with doctors now optimistic that a cure is on the horizon, a marked change from the prospects in 2014 when Chad and Michael were diagnosed. Despite this progress, researchers still have a lot of work to do to change the current survival rate, which is nearly 0%.

“This merger is an exciting and natural step, from my perspective,” said Dr. Carl Koschmann, a pediatric neuro-oncologist in the Department of Pediatrics at Michigan Medicine. “The Carrs and Mosiers both approach DIPG research with a similar emphasis on collaboration, transparency, and improving outcomes in real time. From a research and personal perspective, those of us doing research and clinical care in this space know that these two families/foundations are 100% with us with every step. I’m excited to see that they will now fully merge, and I look forward to moving the needle even faster.” 

While both the Carrs and the Mosiers will always grieve the loss of their sons, creating a legacy that offers hope to other fighting families has given them a way to channel their pain into action. The coming together of these two foundations, of these two families, marks an inflection point in the world of pediatric brain cancer research funding. What started out as tributes to their own sons has evolved to be about much more. They share a deep commitment to honoring every child who has fought DIPG and fighting for every family facing a DIPG diagnosis in the coming weeks, months, and years. And these two families are not alone in that commitment. 

ChadTough Defeat DIPG Foundation believes a collaborative approach is the only way a cure will be found. The foundation therefore welcomes the help of other families who want to join in funding pediatric brain cancer research (with an emphasis on DIPG) in honor of their children through the Family Partner program. They are currently joined by 15 official Family Partners from across the country whose lives have been impacted by pediatric brain cancer and who are committed to the mission of the foundation. This combined power will lead to more funding of more research, with the goal of a cure for DIPG and other pediatric brain cancers sooner than would otherwise be possible.

CHADTOUGH DEFEAT DIPG FAMILY PARTNERS:

The Albom Family: Team Chika
The Boivin Family: Team Julian
The DelVerne Family: #ColtStrong
The Jones Family: Team Carter
The O’Brien Family: Team Caroline
The Olympia Family: Connor Man
The Petrzelka/Shaker Family: Team Owen
The Reinhold/Hatzivasilis Family: Team Benjamin
The Ruddy Family: Team Tommy
The Sawtelle Family: Team Arden
The Sieck Family: Team Lucy
The Steensland Family: Team Grant
The Thompson Family: Team Emma
The Varney Family: #SophieStrong
The Weaver Family: Vivian Rose

ChadTough Defeat DIPG Foundation is laser-focused on achieving its vision of a world where DIPG is no longer a death sentence. By harnessing the collective power of the Carrs, Mosiers, and their Family Partners, the foundation will build on the work they have started and expedite progress towards a cure.

Learn More at chadtough.org.  

---

Michael Mosier Defeat DIPG Foundation, with its chapters and partner families, has made a grant of $100,000 to support the opening of a new Expanded Access Program for ONC201, an experimental drug currently being tested to treat DIPG. From 2018 to 2020, Defeat DIPG has provided $266,666 to support development of ONC201, with a goal of increasing the availability of ONC201 for DIPG patients. Expanded access is a mechanism for patients to access this experimental therapy when the patient is unable to participate in a clinical trial and meets eligibility criteria.

Oncoceutics has issued the following press release to announce the grant.

---

Philadelphia, PA (November 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that it has received grants from Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation to fund an Expanded Access program for ONC201 in the United States. 

The program will allow Oncoceutics to work with physicians practicing in the United States to provide ONC201 to patients with H3 K27M-mutant glioma, including DIPG, who meet certain eligibility criteria and who cannot otherwise access ONC201 by participating in an ongoing clinical trial. The Expanded Access program has been made available to select hospitals across the United States, though accrual is not yet open to patients. A list of centers that are in the process of initiating the program can be found on clinicaltrials.gov along with their contact information: click here. Patients and their families can reach out directly to these centers to discuss treatment options and enrollment timelines, as enrollment activities must be completed by the treating physician and their respective institutions in collaboration with Oncoceutics before a patient can be treated.

“At Oncoceutics, we have made it our mission to help patients with advanced cancers such as H3 K27M-mutant glioma and DIPG, and we are dedicated to advancing the clinical and regulatory development of ONC201 so that many more patients will have access to the treatment,” said Lee Schalop, MD, Chief Executive Officer of Oncoceutics. “We are grateful for the philanthropic support from the Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation as it enables us to provide ONC201 to more patients today while we are working towards our goal of obtaining regulatory approval to help brain tumor patients with ONC201 as a novel therapy.”

“Patients with DIPG and other brain cancers face the devastation of a challenging prognosis coupled with very few treatment options,” said Mark Mosier, Chairman of the Board of Directors of Michael Mosier Defeat DIPG Foundation. “Defeat DIPG, Dragon Master Foundation, and The ChadTough Foundation are funding the ONC201 Expanded Access program to help ensure patients have access to as many options as possible.”

Expanded Access – sometimes called “compassionate use” – provides a pathway for patients to receive an investigational medicine for a serious disease or condition. Expanded Access is often made available when: there are no comparable or satisfactory alternative therapies to treat the disease or condition; patient enrollment in clinical trials is not possible; potential patient benefit justifies the potential risk of treatment; and providing the investigational medicine will not interfere with investigational trials that could support the medicine’s marketing approval for the treatment indication.

ONC201 is an investigational medicine that is being evaluated in Phase I and Phase II trials. Investigational products have not yet been approved or cleared by FDA, and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects.

Requests for Expanded Access to ONC201 must be made by a U.S. licensed physician. Oncoceutics does not currently supply ONC201 outside of the U.S. Physicians can request access for a patient by sending an email to info@oncoceutics.com. For more information about the Expanded Access program, please refer to Oncoceutics’ Expanded Access Policy. FAQs about accessing ONC201 can be found here.

About Oncoceutics

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. ONC201 is an orally active small molecule DRD2 antagonist and ClpP agonist in late-stage clinical development for H3 K27M-mutant glioma with additional indications under clinical investigation. ONC206 is the second clinical-stage imipridone that is under clinical investigation for central nervous system tumors. The company is supported by grants from NCI, FDA, The Musella Foundation, Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation, The ChadTough Foundation, the National Brain Tumor Society, and a series of private and public partnerships. Visit Oncoceutics.com or contact Press@oncoceutics.com for more information.

About Michael Mosier Defeat DIPG Foundation

Michael Mosier Defeat DIPG Foundation works to find a cure for brainstem tumors known as diffuse intrinsic pontine gliomas (DIPG), the deadliest form of childhood brain cancer.  The Foundation focuses on funding innovative research to find treatments for DIPG and raising awareness of this devastating disease.  Visit defeatdipg.org for more information.

About Dragon Master Foundation

Dragon Master Foundation’s mission is to find and accelerate cures for cancers and other diseases by fostering and rewarding a community of collaboration and innovation. We seek to spread awareness, expedite research and kinder treatments, and improve the quality of life for patients and their families. We invite your engagement at www.dragonmaster.org. Dragon Master Foundation’s support included contributions from Friends of Emily Hood, Mithil Prasad Foundation, Musella Foundation for Brain Tumor Research, National Brain Tumor Society, Storm the Heavens Fund, and Team Cozzi Foundation.

About The ChadTough Foundation

The mission of The ChadTough Foundation is to inspire and fund game-changing research to discover effective treatments for pediatric brain cancer, with an emphasis on Diffuse Intrinsic Pontine Glioma (DIPG). Visit www.ChadTough.org for more information.

Michael Mosier Defeat DIPG Foundation and The ChadTough Foundation, with their chapters and partner families, have granted over $600,000 for the Diffuse Midline Glioma – Adaptive Clinical Trial (DMG-ACT), a new collaboration through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and the DIPG Centre of Expertise in Zurich.

This innovative project will support preclinical and clinical work across multiple institutions to move combination therapies for DIPG into the clinic as quickly as possible. Scientists across the world will share their latest preclinical data, greatly enhancing opportunities for research impact and improved patient outcomes.

The DMG-ACT is an international, adaptive clinical trial for diffuse midline gliomas. DMGs are fast-growing, cancerous tumors found in the midline of the brain, and they include diffuse intrinsic pontine glioma (DIPG) tumors.

“We’ve developed a clinical trial protocol, with multiple arms, where we will use evidence from multiple labs to bring the best combination therapies forward,” says Dr. Sabine Mueller, pediatric neuro-oncologist of University of California, San Francisco and Clinical Program Head at DIPG Centre of Expertise in Zurich. “Initially, our main concern is if drugs are really getting into the tumor of these devastating diffuse midline gliomas. If we do not see any early signs of survival impact, we will also look at drug penetration to decide if an arm should be adjusted or closed.” 

The other key focus of this program will be to offer combination therapies at each stage of the disease (newly diagnosed, post-radiation, and upon recurrence). In addition to new promising combinations, many critical studies will be performed (biopsies, blood draws, and lumbar punctures) for real-time analysis at labs around the world to learn which treatments are working and why. This trial setup is unprecedented for pediatric diffuse midline glioma. 

“PNOC has a very well organized and motivated clinical trial infrastructure in San Francisco and Zurich that allows trials to open quickly, complete quickly, and share data quickly. This allows us to speed up translating discoveries in the lab to the bedside and share our data with colleagues around the world in real time,” said Michigan Medicine pediatric oncologist Dr. Carl Koschmann, who serves as a PNOC site co-principal investigator.  PNOC is an international consortium with study sites within the United States, Canada, Europe and Australia.

Like many PNOC trials, DMG-ACT will require or offer sequencing along with the therapy, depending on the diagnosis. This data will be deposited into a central PNOC database that allows researchers within and outside of PNOC to access de-identified data. Researchers will then be able to work together to design the future generation of trials while also re-evaluating current trials.

The protocol for DMG-ACT is different from typical clinical trials in that it studies smaller groups of patients (15 to 20). Patients are then added or transitioned to other treatments based on initial findings. This design allows the trial to proceed much quicker than typical early-phase clinical trials.

As part of this trial, a consortium of more than 10 international labs (the DMG-ACT Pre-Clinical Team) has been studying single and combinatorial treatments on models of DMG. This data is then shared with the DMG-ACT Clinical Team. The drugs that are the most promising pre-clinically are then selected for use in combination in an arm of DMG-ACT. Once selected, the Pre-Clinical Team works to develop markers of treatment response to look for in the tissue and liquid samples that clinicians will collect from patients.

Researchers at PNOC are currently finalizing the protocol and agreement with sponsors of the initial combinations. The first arm of the trial should be open for enrollment early fall 2020 and includes the combination of ONC201 and panobinostat.

“Simply put,” said Dr. Koschmann, “the trial would not be opening this year without the current and future support of Michael Mosier Defeat DIPG Foundation and The ChadTough Foundation. Their early and generous support of DMG-ACT allowed us to remove all brakes to get all aspects of the infrastructure created and get the trial open, with the international scale of pre-clinical and clinical aspects we felt our patients needed. For those of us involved with this trial, we feel this is the trial that will finally provide the jumps in improved survival for DMG that was seen in leukemia 40 to 50 years ago. It is fitting that Michael Mosier Defeat DIPG Foundation and The ChadTough Foundation are part of our team for this.”

Frequently Asked Questions

Q: When will the trial open for enrolling patients?

We are currently estimating that the trial will be finalized in Fall 2020.  The earliest site openings are expected in late 2020, with broader openings in 2021.

Q: How can I find out if my child qualifies for this trial?

When the trial is finalized, more detailed information, including eligibility criteria, will be available through www.pnoc.us and www.clinicaltrials.gov

Q: What can I do to be ready to enroll when the trial opens?  

When the trial opens, patients (or their parents) may contact their nearest PNOC site, and let them know you would like to be considered for the DMG-ACT trial PNOC sites are listed at www.pnoc.us, or email PNOC at PNOC_Regulatory@ucsf.edu for further details.

Q: My child is currently enrolled in a different trial.  Can I switch to DMG-ACT so my child can get a combination therapy?

There are three cohorts to the trial in its current form: (1) newly diagnosed (before radiation), (2) post-radiation (before progression), and (3) at progression/relapse. It is less likely that a patient would be eligible for one of these cohorts if currently on a clinical trial without progression.

Q: Is it possible for my child to be involved in the trial, yet receive treatments at our own cancer center?

Treatment/enrollment will only be through PNOC sites. It is possible that some of the care can be performed locally.

Q: Will there be a required washout period before starting the trial?

Yes, washout periods will be similar to other clinical trials and will depend on which arm you enroll.

Michael Mosier Defeat DIPG^®Foundation, a nonprofit whose mission is finding a cure for the deadliest pediatric brain cancer, DIPG (diffuse intrinsic pontine glioma), announced today the addition of a chapter in Gresham, Oregon, to its Defeat DIPG^®Network:  Levi Harden Defeat DIPG^®Foundation. Today would have been Levi Harden’s fourth birthday. Levi passed away from DIPG in October 2019, at three years old, just two months after diagnosis.

The new chapter adds to Defeat DIPG Network’s existing presence across the United States, in Maryland and Washington, D.C. as Michael Mosier Defeat DIPG Foundation, in Illinois as Anthony’s Avengers Defeat DIPG^®Foundation, in Texas as Connor Man Defeat DIPG^®Foundation, and in Washington as Avery Huffman Defeat DIPG^®Foundation and Vivian Rose Weaver Defeat DIPG^®Foundation. The Defeat DIPG Network has raised over $7.4 million for DIPG research in less than 5 years.

The Oregon chapter, which will operate as Levi Harden Defeat DIPG Foundation, is founded in memory of Levi Harden, son of Jenica and Nathan Harden. Levi loved sports, and from just two years old he could play miniature golf, hit a golf ball across the yard, play baseball, shoot hoops for hours and throw football with a perfect spiral. Levi was full of laughter and love and adored his big brother Clayton and new little sister Erin who was born around three weeks before his diagnosis with DIPG. 

“We believe the best way to honor our son’s memory is to continue his fight against the disease that took his precious life,” says Jenica Castillo-Harden, Levi’s mother who will serve as Director of Levi Harden Defeat DIPG Foundation. “We are committed to finding a cure for DIPG because we believe that every child deserves a chance to grow up.  No family should have to hear their child’s doctor say, ‘there is nothing we can do.’ We know that together with our Defeat DIPG partners, we can change the future for kids with DIPG.” 

Jenny and Mark Mosier created Michael Mosier Defeat DIPG Foundation in June 2015 to fund DIPG research and promote awareness of the disease, after the passing of their 6-year-old son, Michael. With its geographic expansion and growth of existing initiatives, the Foundation expects to continue to increase its capacity to fund essential childhood cancer research.  

The Foundation, with its chapters, has announced over $7 million in DIPG-specific research funding, in partnership with The ChadTough Foundation. Two grants are also in partnership with SoSo Strong Pediatric Brain Tumor Foundation. Michael Mosier Defeat DIPG Foundation works with a preeminent Scientific Advisory Council of brain tumor experts that advises its Board of Directors on how to maximize its resources to fund research for a cure for DIPG. 

The Mosier, Harden, Gaskin, Huffman, Olympia, and Weaver families will work to grow the already powerful base of support in each of their communities, and to honor and unite all children and families who have had to confront this disease.  

“It is an honor to stand side-by-side with other families who share such a deep passion and dedication for finding a cure for DIPG,” says Jenny Mosier, Executive Director of Michael Mosier Defeat DIPG Foundation. “The devastating experience of losing our own children inspires our work to improve the dismal prognosis of less than 1% survival for children with DIPG. By driving more resources to DIPG research, we are pushing the field forward to find treatments for these children.” 

DIPG is the deadliest form of pediatric brain cancer, with a median survival from diagnosis of 9 months and a near 0% survival overall. DIPG typically strikes children between ages four and eleven. Because of its location in the brainstem where all motor activity is controlled, DIPG is inoperable. The disease progresses by taking over a child’s motor functions one-by-one, typically starting with vision and balance problems, before moving to partial paralysis, followed by the inability to chew, speak, swallow, move and eventually breathe – all of this while the child remains mentally intact.

For decades, treatment for DIPG has remained the same and has been ineffective. The entire amount spent annually on DIPG research – approximately $3 – 5 million – is less than 0.0005% of the total funding for cancer research.  In just the past few years, due to better medical technology and increased access to tumor tissue, researchers have made real advances in their understanding of this disease.  There is finally hope for progress in finding a cure.

Learn more about our new chapter at levidefeatdipg.org.

Families, researchers, government regulators, and advocates gathered in Washington, DC, on February 13, 2020, for a multi-part event for the DIPG community, organized by the DIPG Advocacy Group.  There was an excellent turnout from throughout the country, a powerful example of collaboration and persistence of families who will not stop pushing to do better for the children facing DIPG (diffuse intrinsic pontine glioma). 

In the morning, a Congressional Briefing was held to educate Congressional offices and advocate for passage of H. Res. 114, a resolution to support establishing May 17 as DIPG Awareness Day and encouraging greater consideration for pediatric and high mortality-rate cancers in the research grant process with public and private funding sources.  We thank Congresswoman Jackie Speier for her support for this important event.  There are nearly 100 co-sponsors for the bill to date, but additional support is needed.  Following the briefing, attendees gathered for a State of DIPG Summit that involved discussion of hot topics in the community, such as research initiatives, challenges facing patients and families, development of ONC201, the FDA regulatory framework, data-sharing, and advocacy opportunities.  A listing of speakers is below.

A highlight of the day was hearing from three patients:  young adults who are currently fighting DIPG and DMG (diffuse midline glioma).  Jace Ward, Anjalie Bartee, and Katie Bedingfield spoke with strength and passion about the reality for young adults and children fighting this difficult disease.  They emphasized the urgency of driving research forward and drawing more attention to the needs of this vulnerable population.

“I can’t promise I’ll be back here next year.  Which is exactly why I respectfully ask you to co-sponsor H. Res. 114 before you leave for the weekend. DIPG won’t wait until this is convenient. DIPG won’t wait until we are ready. While we have been ‘waiting’ to take a solid stand, DIPG has been taking the sight, the hearing, the speech, the ability to swallow and eventually the breath of thousands of kids across this country.” — Jace Ward, 21 years old, fighting DIPG since May 17, 2019.

A number of other families in the midst of the fight with their child made an incredible effort to take part in the event, including the Basha family from New York (with Elita in attendance), Halek family from Illinois (with Noah in attendance), and Stacey Sands from Kansas (in honor of Hudson).  And there were countless families who carry the heartbreak of losing a child who took part in memory of their precious children.  The power of standing together as a united community was palpable.  

Michael Mosier Defeat DIPG Foundation was proud to sponsor this event alongside other organizations:  The ChadTough Foundation, Dragon Master Foundation, Jack’s Angels Foundation, Julia Barbara Foundation, Smashing Walnuts Foundation, and Team Cozzi Foundation.  We thank Covington & Burling LLP for generously hosting the State of DIPG Summit and Akin Gump LLP for supporting the Congressional Briefing effort.  We appreciate the hospitality and great food from We, The Pizza, a restaurant owned by The Mendelsohn Family who are steadfast supporters of the fight to Defeat DIPG.

YOU CAN TAKE ACTION

There are two immediate action items where all can contribute to the coordinated efforts to establish May 17 as DIPG Awareness Day, as a catalyst for increased attention to this tragic disease.

Support H. Res. 114 – Federal Recognition

The DIPG Advocacy Group has detailed information on how you can engage with your Congressional representative to urge their participation as a co-sponsor for H. Res. 114.  Please visit the DIPG Advocacy Group website for instructions on how to contact the legislator who represents your district, either to request their support or to thank them for signing on to the resolution. 

Support “DIPG Across the Map” – State Level Recognition  

We call on everyone to use their stories and voice to help get all 50 states to recognize May 17 as DIPG Awareness Day.  To sign up for this project, please visit www.defeatdipg.org/dipgacrossthemap.  Michael Mosier Defeat DIPG Foundation organizes this project – a collaboration of foundations and individuals throughout the country – as a companion effort to our federal efforts.  We will provide step-by-step instructions and materials to assist in advocating within your state.  In 2019, 32 states recognized May 17 as DIPG Awareness Day.  We hope to increase that number in 2020, with the collective effort of the DIPG Community.

*****

Congressional Briefing Speakers

Janet Demeter (Jack’s Angels Foundation), Sabine Mueller (University of California San Francisco and [zurich]), Adam Resnick (Children’s Hospital of Philadelphia and Children’s Brain Tumor Tissue Consortium), Charles Keller (FILL IN), Malcolm Smith, David Arons (National Brain Tumor Society), Jace Ward (DIPG patient), Jenny Mosier (Michael Mosier Defeat DIPG Foundation), Elizabeth and William Psar (Julia Barbara Foundation, and Jill, Cam, and Phebe Morin (Luke’s Posse). Video available at this link.

State of DIPG Summit Speakers

Mark Mosier (Michael Mosier Defeat DIPG Foundation), Janet Demeter (Jack’s Angels Foundation), Elizabeth Psar (Julia Barbara Foundation), Paul Miller (advocate), Jenny Mosier (Michael Mosier Defeat DIPG Foundation), Sabine Mueller, MD, PhD (University of California San Francisco and [zurich]), Eugene Hwang, MD (Children’s National Hospital), Carl Koschmann, MD (University of Michigan), Paul Cozzi (Team Cozzi Foundation), Katie Gaskin (Anthony’s Avengers Defeat DIPG Foundation), Anjalie Bartee (patient), Katie Bedingfield (patient), Wolfgang Oster, MD, PhD (Oncoceutics), Amanda Haddock (Dragon Master Foundation), Adam Resnick (Children’s Hospital of Philadelphia and Children’s Brain Tumor Tissue Consortium), Gregory Reaman, MD (U.S. Food and Drug Administration), Jonathan Agin (Max Cure Foundation, Oncoheroes Biosciences), Danielle Leach (National Brain Tumor Society), and Jace Ward (patient). Video available at this link.